The promising results in human studies have been shown by an experimental coronavirus vaccine developed by Beijing’s China National Biotec Group (CNBG). The business said on Sunday that early testing revealed that the experimental vaccine COVID-19 against the SARS-CoV-2 virus might be healthier and more successful.
According to CNBG, which is associated with the state-owned China National Pharmaceutical Group (Sinopharm), it was the company’s second vaccine candidate to develop promising results in a clinical trial. In a post on the WeChat social media website, CNBG reported that preliminary results from the trial involving 1,120 healthy people showed that the experimental vaccine produced high-level antibodies in all inoculated participants in a Phase 1/2 clinical test.
The Institute in Beijing has reported in its statement that after two doses of the vaccine all voluntary professionals have developed antibodies against the novel coronavirus. According to reports, China is the main front runner in the COVID-19 jab market and is working in developing five types of coronavirus vaccines-inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines, and nucleic acid-based vaccines.
On 23 June, CNBG announced that its vaccine candidate in the United Arab Emirates will conduct a Phase 3 trial, although the company has not revealed what vaccine will be tested. In the ‘Phase 3’ human study involving thousands of participants, a vaccine must demonstrate its effectiveness for widespread use.
Read More News: Click Here